Age-associated increase in interleukin 6 in MRL/lpr mice
- PMID: 2049341
- DOI: 10.1093/intimm/3.3.273
Age-associated increase in interleukin 6 in MRL/lpr mice
Abstract
It has been demonstrated that abnormal expression of interleukin 6 (IL-6) may be involved in the pathogenesis of a variety of autoimmune diseases and glomerulonephritis. In this study, we demonstrate an age-associated increase in IL-6 in the sera of MRL/lpr mice but not in control congenic MRL/+ mice, normal strains of BALB/c, C3H/HeN mice, and other autoimmune prone mice, such as (NZB x NZW)F1, (NZB x BXSB)F1 mice. IL-6 activity was detected in the sera of MRL/lpr mice by 3 weeks of age and it was neutralized by anti-mouse IL-6 antibody. The serum IL-6 level was gradually increased with age and reached up to 410 pg/ml around 30 weeks of age. The expression of IL-6 mRNA was detected in the spleen and lymph nodes from 8 weeks of age. Expression of IL-6 mRNA was also detected in C57BL/6-lpr mice, indicating the possible linkage of abnormal expression of the IL-6 gene and the lpr gene. Southern blot analysis demonstrated that both the promoter region and 3' untranslated region of the IL-6 gene were apparently normal, suggesting that deregulated production of IL-6 may be due to abnormal transcriptional control. The data suggest that abnormal expression of the IL-6 gene may play a key role in the development of polyclonal B cell activation and glomerulonephritis in MRL/lpr mice.
Similar articles
-
Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal.Eur J Immunol. 1993 May;23(5):1078-82. doi: 10.1002/eji.1830230515. Eur J Immunol. 1993. PMID: 8477802
-
Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB x NZW)F1 and MRL/MpJ-lpr/lpr mice.J Immunol. 1993 Dec 1;151(11):6509-16. J Immunol. 1993. PMID: 7902378
-
Oncogene expression in autoimmune mice.J Mol Cell Immunol. 1985;2(3):121-31. J Mol Cell Immunol. 1985. PMID: 3916923
-
Autoimmune diseases as stem cell disorders.Tohoku J Exp Med. 1994 May;173(1):141-55. doi: 10.1620/tjem.173.141. Tohoku J Exp Med. 1994. PMID: 7809904 Review.
-
Cytokine dysregulation and the initiation of systemic autoimmunity.Immunol Lett. 1994 Dec;43(1-2):15-21. doi: 10.1016/0165-2478(94)00144-8. Immunol Lett. 1994. PMID: 7737685 Review.
Cited by
-
Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.Int J Rheumatol. 2012;2012:946048. doi: 10.1155/2012/946048. Epub 2012 Jan 18. Int J Rheumatol. 2012. PMID: 22315615 Free PMC article.
-
MT-CO1 expression in nine organs and tissues of different-aged MRL/lpr mice: Investigation of mitochondrial respiratory chain dysfunction at organ level in systemic lupus erythematosus pathogenesis.Arch Rheumatol. 2022 Jul 29;37(4):504-516. doi: 10.46497/ArchRheumatol.2022.9168. eCollection 2022 Dec. Arch Rheumatol. 2022. PMID: 36879572 Free PMC article.
-
Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.J Clin Invest. 2003 Feb;111(4):539-52. doi: 10.1172/JCI16153. J Clin Invest. 2003. PMID: 12588892 Free PMC article.
-
IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice.Clin Exp Immunol. 1998 Jun;112(3):397-402. doi: 10.1046/j.1365-2249.1998.00612.x. Clin Exp Immunol. 1998. PMID: 9649207 Free PMC article.
-
Pathways leading to an immunological disease: systemic lupus erythematosus.Rheumatology (Oxford). 2017 Apr 1;56(suppl_1):i55-i66. doi: 10.1093/rheumatology/kew427. Rheumatology (Oxford). 2017. PMID: 28375453 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical